Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123338 | 0.84 | PPARA (0.55) | HDAC6HDAC1PPARAPPARGCNR1 | |
| SCHEMBL24847857 | 0.83 | PPARA (0.51) | HDAC6HDAC1PPARAPPARGCNR1 | |
| SCHEMBL23845447 | 0.82 | PPARA (0.49) | HDAC6HDAC1PPARAPPARGCNR1 | |
| SCHEMBL26224287 | 0.82 | PPARA (0.49) | HDAC6HDAC1PPARAPPARGCNR1 | |
| SCHEMBL26203900 | 0.77 | FOS (0.47) | HDAC6HDAC1PPARAPPARGMTNR1A | |
| SCHEMBL19130712 | 0.77 | MAPT (0.65) | HDAC6HDAC1MAPT | |
| SCHEMBL19130442 | 0.77 | MAPT (0.65) | HDAC6HDAC1MAPT | |
| SCHEMBL2625206 | 0.77 | MAPT (0.65) | HDAC6HDAC1MAPT | |
| SCHEMBL12398374 | 0.77 | MAPT (0.65) | HDAC6HDAC1MAPT | |
| SCHEMBL25834869 | 0.77 | MAPT (0.65) | HDAC6HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | HDAC6 272/4885HDAC1 609/4885PPARA 3003/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | HDAC6 1036/4885HDAC1 1505/4885PPARA 2341/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | HDAC6 181/4885HDAC1 930/4885PPARA 1856/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | HDAC6 181/4885HDAC1 930/4885PPARA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.